Upstream Bio, Inc. (UPB)
| Market Cap | 455.50M -4.2% |
| Revenue (ttm) | 3.32M +44.7% |
| Net Income | -156.76M |
| EPS | -2.90 |
| Shares Out | 54.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,422 |
| Open | 8.47 |
| Previous Close | 8.46 |
| Day's Range | 8.33 - 8.69 |
| 52-Week Range | 7.25 - 33.68 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 42.43 (+406.93%) |
| Earnings Date | May 13, 2026 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Financial Performance
In 2025, Upstream Bio's revenue was $2.85 million, an increase of 20.42% compared to the previous year's $2.37 million. Losses were -$143.44 million, 87.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for UPB stock is "Buy." The 12-month stock price target is $42.43, which is an increase of 406.93% from the latest price.
News
Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
Upstream Bio (UPB) presented new data from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps. The data, presented in two posters at the…
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and c...
Upstream Bio price target lowered to $50 from $51 at Mizuho
Mizuho lowered the firm’s price target on Upstream Bio (UPB) to $50 from $51 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
“We continue to make strong progress advancing our clinical programs in severe asthma and CRSwNP to position verekitug as a uniquely differentiated treatment option for these diseases,” said Rand Suth...
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mi...
Upstream Bio Earnings release: Q1 2026
Upstream Bio released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Upstream Bio Quarterly report: Q1 2026
Upstream Bio has published its Q1 2026 quarterly earnings report on May 13, 2026.
Upstream Bio Slides: Corporate presentation
Upstream Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
Upstream Bio (UPB) announced two upcoming poster presentations at the American Thoracic Society 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new dat...
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirat...
Upstream Bio Proxy statement: Proxy filing
Upstream Bio filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Upstream Bio Proxy statement: Proxy filing
Upstream Bio filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Upstream Bio Slides: Corporate presentation
Upstream Bio has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Upstream Bio (UPB) to In Line from Outperform with a price target of $15, down from $40. While the firm remains “optimistic” on verekitug and believes the…
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company...
Upstream Bio Annual report: Q4 2025
Upstream Bio has published its Q4 2025 annual report on March 26, 2026.
Upstream Bio Earnings release: Q4 2025
Upstream Bio released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Upstream Bio Slides: Corporate presentation
Upstream Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Upstream Bio Transcript: Leerink Global Healthcare Conference 2026
Verekitug demonstrated strong efficacy and quarterly dosing in phase II asthma trials, with plans to start phase III in severe asthma and CRSwNP by early next year. The COPD program is over 60% enrolled, and device development is progressing in parallel. Cash runway extends through 2027.
Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference
Verekitug demonstrated strong efficacy and safety in phase II trials for asthma and CRSwNP, with quarterly dosing matching or exceeding competitors. Phase III trials are planned for year-end, with advanced manufacturing and regulatory preparations supporting a rapid path to market.
Upstream Bio announces verekitug met the primary endpoint
Upstream Bio (UPB) presented additional data from the Phase 2 Vibrant clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps. The additional analyses incorpo...
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provide...
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –
Upstream Bio to Participate in Upcoming March Investor Conferences
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirator...
Upstream Bio Transcript: Study result
VALIANT phase II results show verekitug significantly reduced asthma exacerbations and improved lung function and biomarkers at both 12- and 24-week dosing intervals, with a favorable safety profile. These findings support advancing to phase III trials in severe asthma and CRSwNP.